TIGIT cancer immunotherapy may be made more effective by combining it with additional “braker” drugs, such as anti-CTLA-4, anti-vascular endothelial growth factor (VEGF), a triple combination of TIGIT+PD-1/PD-L1+CTLA-4 or TIGIT+PD-1/PD-L1+VEGF, or chemotherapy. This evidence concerns the gene PDCD1 and cancer.